The Brain Tumor Center, The University of Chicago Pritzker School of Medicine, 5841 South Maryland Ave, MC 3026, Chicago, IL 60637, USA.
Stem Cell Rev Rep. 2011 Mar;7(1):119-29. doi: 10.1007/s12015-010-9132-7.
Cancer stem cells (CSC) are a very small subset of all cancer cells and possess characteristics very similar to normal stem cells, in particular, the capacity for self-renewal, multipotency and relative quiescence. These chemo- and radiation resistant cells are responsible for maintaining tumor volume leading to therapy failure and recurrence. In glioblastoma multiforme (GBM), the most common primary intracranial malignancy, glioma stem cells have been implicated as one of the key players in treatment failure. Many novel treatment modalities are being investigated to specifically target this small group of cells. In this review, we shed light on one such targeted therapy, specifically, oncolytic virotherapy, and review the literature to highlight the advances and challenges in designing effective oncolytic virotherapy for glioma stem cells.
癌症干细胞（CSC）是所有癌细胞中非常小的一部分，它们具有与正常干细胞非常相似的特征，特别是自我更新、多能性和相对静止的能力。这些化疗和放疗耐药的细胞负责维持肿瘤体积，导致治疗失败和复发。在多形性胶质母细胞瘤（GBM）中，最常见的原发性颅内恶性肿瘤，神经胶质瘤干细胞已被认为是治疗失败的关键因素之一。许多新的治疗方法正在被研究，以专门针对这一小群细胞。在这篇综述中，我们重点介绍了一种靶向治疗方法，即溶瘤病毒治疗，并回顾了文献，强调了设计针对神经胶质瘤干细胞的有效溶瘤病毒治疗的进展和挑战。
